ReviewCancers2018
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy.Nature communications · 2024Article
- Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Thoracic cancer · 2024Article
- Review
- The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer.OncoTargets and therapy · 2024Review
- Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.Frontiers in oncology · 2024Article
- Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.Frontiers in immunology · 2023Article
- Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.International journal of molecular sciences · 2022Article
- The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.Translational lung cancer research · 2022Review
- Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer.Cancers · 2021Review
- Article
- Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Cancer medicine · 2021Article
- Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.Virchows Archiv : an international journal of pathology · 2020Article
- Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response.Clinical and translational medicine · 2020Article
- Association between interleukin-36γ and tumor progression in non-small cell lung cancer.Oncology letters · 2020Article
- Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer.Translational cancer research · 2019Article
- Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.International journal of molecular sciences · 2019Review
- KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.Cancers · 2019Article
- Dual inhibition of MEK and p38 impairs tumor growth inOncology letters · 2019Article
- Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges.Precision clinical medicine · 2019Review
- Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical application of immune checkpoint inhibitors (ICIs) has led to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC). Despite the observation of improved overall survival in NSCLC patients treated with ICIs, their efficacy varies greatly among different immune and molecular profiles in tumors. Particularly, the clinical significance of ICIs for oncogene-driven NSCLC has been controversial. In this review, we provide recent clinical and preclinical data focused on the relationship between oncogenic drivers and immunological characteristics and discuss the future direction of immunotherapy in NSCLC patients harboring such genetic alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.